| Recruiting | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia NCT07504458 | Quetzal Therapeutics | Phase 3 |
| Not Yet Recruiting | A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokin NCT07296445 | SDK Therapeutics, Inc. | Phase 3 |
| Enrolling By Invitation | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients NCT06544109 | The First Affiliated Hospital of Soochow University | Phase 2 / Phase 3 |
| Recruiting | Optimum Induction Therapy of Low-risk APL NCT05832320 | Peking University People's Hospital | N/A |
| Suspended | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia NCT04996030 | Syros Pharmaceuticals | Phase 1 |
| Recruiting | Frontline Oral Arsenic Trioxide for APL NCT04687176 | The University of Hong Kong | Phase 2 |
| Unknown | Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Le NCT03751917 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Unknown | The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project NCT04251754 | The University of Hong Kong | — |
| Recruiting | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia NCT04793919 | Associazione Italiana Ematologia Oncologia Pediatrica | Phase 2 |
| Unknown | Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia NCT03624270 | The University of Hong Kong | Phase 2 |
| Unknown | Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy NCT03096496 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Unknown | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) NCT02899169 | First Affiliated Hospital Xi'an Jiaotong University | Phase 3 |
| Completed | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia NCT02688140 | Technische Universität Dresden | Phase 3 |
| Active Not Recruiting | French Registry of First-line Treatment of Acute Promyelocytic Leukemia NCT02938858 | Groupe Francophone des Myelodysplasies | — |
| Unknown | Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia NCT02991066 | First Affiliated Hospital of Harbin Medical University | — |
| Completed | A Safety Study of SGN-CD33A in AML Patients NCT01902329 | Seagen Inc. | Phase 1 |
| Completed | Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia NCT01910623 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Unknown | Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL NCT01987297 | Shanghai Jiao Tong University School of Medicine | Phase 4 |
| Completed | Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemothe NCT01472107 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followe NCT01404949 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia NCT00670150 | University of Southern California | Phase 2 |
| Terminated | Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia NCT00985530 | Northwestern University | Phase 1 |
| Terminated | ASCT for Relapsed APL After Molecular Remission NCT00907582 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Unknown | Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia NCT01226303 | Associazione Italiana Ematologia Oncologia Pediatrica | Phase 3 |
| Unknown | Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia NCT00675870 | NuRx Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in NCT00852709 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL NCT00520208 | CytRx | Phase 2 |
| Completed | Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) NCT00504764 | PETHEMA Foundation | Phase 4 |
| Completed | All-trans Retinoic Acid, and Arsenic +/- Idarubicin NCT00413166 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) NCT00408278 | PETHEMA Foundation | Phase 4 |
| Unknown | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia NCT00517712 | Christian Medical College, Vellore, India | Phase 2 / Phase 3 |
| Unknown | AIDA 2000 Guidelines NCT01064570 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Active Not Recruiting | Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia NCT00003861 | Alliance for Clinical Trials in Oncology | — |
| Completed | Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) NCT00465933 | PETHEMA Foundation | Phase 4 |